Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead's Strong HIV Quarter Plus Bictegravir May Portend Sector Dominance

Executive Summary

Sales of Gilead's TAF-based regimens for HIV continue to grow and should be augmented by elvitegravir successor bictegravir. The company's future growth is unclear, however, without M&A.

Advertisement

Related Content

Gilead Raises HCV Guidance Slightly, Still Mum On M&A
2Q Pharma Results Preview: Lilly, Biogen, Amgen, GSK And Gilead
J&J's Quad HIV Combo Likely To Pass CHMP; EU Market Uptake Is Trickier
Gilead's Bictegravir Demonstrates Broad Non-Inferiority, But Will That Suffice?
Genfit's Enrollment Delay In NASH May Aid Intercept's First-To-Market Goal
Gilead Admits It Needs M&A To Resume Growth, But Stays Quiet
Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground
Gilead HIV Sales Getting Boost From Switches To TAF-Based Combos
Filgotinib Progress At Higher Dose Justifies Gilead's Gamble

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099220

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel